Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canagliflozin with anti-tuberculosis chemotherapy in pulmonary tuberculosis with type 2 diabetes
ChiCTR2600118444Phase 4Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of canagliflozin in pulmonary tuberculosis (TB) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoints: Conversion rate of sputum culture and Cure rate. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
canagliflozin
03
Conditions
pulmonary tuberculosis (TB)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2600118444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118444.